As of 2024-12-12, the Relative Valuation of Revance Therapeutics Inc (RVNC) is (25.91) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.04 USD, the upside of Revance Therapeutics Inc based on Relative Valuation is -952.1%.
The range of the Relative Valuation is (14.62) - (35.20) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 10.5x - 25.2x | 18.5x |
| Forward P/E multiples | 10.0x - 25.8x | 18.6x |
| Fair Price | (14.62) - (35.20) | (25.91) |
| Upside | -580.8% - -1257.9% | -952.1% |
| Date | P/E |
| 2024-12-03 | -2.77 |
| 2024-12-02 | -2.67 |
| 2024-11-29 | -2.59 |
| 2024-11-27 | -2.71 |
| 2024-11-26 | -2.88 |
| 2024-11-25 | -2.72 |
| 2024-11-22 | -2.67 |
| 2024-11-21 | -2.75 |
| 2024-11-20 | -2.72 |
| 2024-11-19 | -2.70 |
| 2024-11-18 | -2.86 |
| 2024-11-15 | -2.99 |
| 2024-11-14 | -3.09 |
| 2024-11-13 | -3.04 |
| 2024-11-12 | -2.96 |
| 2024-11-11 | -2.47 |
| 2024-11-08 | -2.65 |
| 2024-11-07 | -4.14 |
| 2024-11-06 | -4.17 |
| 2024-11-05 | -4.19 |
| 2024-11-04 | -4.17 |
| 2024-11-01 | -4.16 |
| 2024-10-31 | -4.23 |
| 2024-10-30 | -4.24 |
| 2024-10-29 | -4.24 |
| 2024-10-28 | -4.23 |
| 2024-10-25 | -3.37 |
| 2024-10-24 | -3.80 |
| 2024-10-23 | -3.79 |
| 2024-10-22 | -3.79 |
| 2024-10-21 | -3.79 |
| 2024-10-18 | -3.79 |
| 2024-10-17 | -3.71 |
| 2024-10-16 | -3.79 |
| 2024-10-15 | -3.73 |
| 2024-10-14 | -3.69 |
| 2024-10-11 | -3.79 |
| 2024-10-10 | -3.77 |
| 2024-10-09 | -3.76 |
| 2024-10-08 | -3.74 |
| 2024-10-07 | -3.82 |
| 2024-10-04 | -3.74 |
| 2024-10-03 | -3.77 |
| 2024-10-02 | -3.72 |
| 2024-10-01 | -3.73 |
| 2024-09-30 | -3.72 |
| 2024-09-27 | -3.84 |
| 2024-09-26 | -3.86 |
| 2024-09-25 | -3.80 |
| 2024-09-24 | -3.94 |